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Henriette Vind Thaysen1*, P Jess2,3, Søren Laurberg1 and M Groenvold4,5Abstract
Background: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life colorectal
questionnaire module (QLQ-CR38) was developed in 1999, and an update, the QLQ CR29 was published recently.
To date the Danish version of the questionnaire has not been validated. The aim of this study was to examine the
psychometric properties of the Danish version of EORTC QLQ-CR38.
Methods: EORTC QLQ-CR38 was administered to 190 patients with colorectal cancer in two Danish hospitals, one
month after their operation. A psychometric evaluation of the questionnaire’s structure, reliability, convergent,
divergent and known-groups validity was performed.
Results: Data from 164 (86.3%) patients were available for analysis. The Danish version of EORTC QLQ-CR38 showed
satisfactory psychometric properties for the scales: body image, sexual functioning, male sexual problems and
defecations problems. Suboptimal psychometric performances were found for the scales: micturition problems,
symptoms of the gastrointestinal tract and weight loss. Evaluation of the psychometric properties of the scale
chemotherapy side effects was limited by the low number of patients receiving chemotherapy. It was not possible
to assess the psychometric properties of the scale female sexual problems and the single item sexual enjoyment
due to a high number of missing values. The homogeneity of the study population made the evaluation of
known-group validity difficult.
Conclusions: The results of this study suggest that the validity of the Danish version of EORTC QLQ-CR38 is
acceptable. Furthermore, the results support the appropriateness of the updated version, the EORTC QLQ-CR29.
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Health-related quality of life (HRQoL) has become an
important outcome endpoint in cancer research and can
be measured by generic and/or disease – specific instru-
ments. A specific instrument for colorectal cancer
patients, the European Organisation for Research and
Treatment of Cancer (EORTC), quality of life colorectal
questionnaire module (QLQ-CR38), was developed in
1999 by EORTC [1]. EORTC QLQ-CR38 was designed* Correspondence: henrthay@rm.dk
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reproduction in any medium, provided the oras a supplement to the core questionnaire (EORTC
QLQ-C30), which assesses HRQoL of patients with can-
cer, but is not specific for any kind of cancer. EORTC
QLQ-CR38 looks into important issues relevant for
colorectal cancer, such as bowel, bladder, and sexual dys-
function as well as problems in relation to stoma func-
tion. It has been translated into several languages,
including Danish. The Danish version was devised based
on forward-backward translation and pilot-testing
among patients, as described in the guidelines of
EORTC [2]. An update and international validation of
EORTC QLQ-CR38 were undertaken between 2007–
2009, resulting in a shorter version of the questionnaire,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of EORTC QLQ-CR38 has been used in Danish re-
search, the questionnaire has never been formally vali-
dated, which is also the case with other Scandinavian
versions.
Aim
The aim of this study was to examine the psychometric
properties of the Danish version of EORTC QLQ-CR38,
in post-surgical colorectal cancer settings.
Methods
Patients
EORTC QLQ-CR38 and EORTC QLQ-C30 were admi-
nistrated to patients with colorectal cancer treated at
Hillerød Hospital and Aarhus University Hospital ap-
proximately one month after their operation. This was
carried out as part of their participation in two rando-
mized, international, multi-centre studies: Colorectal
cancer laparoscopic or open resection (COLOR II) [5]
(only Hillerød Hospital) and COLOFOL [6]. COLOR II
was designed to investigate short- and long-term out-
comes of open versus laparoscopic surgery for rectal
cancer [5]. In COLOFOL the effects of two different
frequencies of surveillance programs following radical
resection for colorectal cancer on mortality, recurrence-
free survival, cost-effectiveness and quality of life were
examined [6]. In both studies, the patients completed
the questionnaires during a follow-up visit in the out-
patient clinic. A research nurse was present to introduce
the patients to the questionnaire. The patients were
instructed to fill out the questionnaire by themselves. In-
clusion criteria were as defined in the two studies [5,6].
Clinical and sociodemographic data were extracted
from the Danish Colorectal Cancer Group (DCCG)
database. Data for this database are collected by all sur-
gical departments in Denmark and are obtained through
questionnaires filled in by the patients and surgeons.
Complications were defined as postoperative complica-
tions occurring within 30 days after surgery, and were
divided into surgical and medical complications. Infor-
mation concerning the presence of stoma was acquired
from the question “yes or no to stoma” from EORTC
QLQ-CR38. Data were collected between April 2007
and June 2010. Written consent was obtained when
patients first entered COLOR II and COLOFOL.
Questionnaires
EORTC QLQ-CR38 was developed to be used in con-
junction with EORTC QLQ-C30 [7]. It incorporates two
functional scales: body image and sexual functioning:
and two single items assessing future perspective and
sexual enjoyment. The seven symptom scales comprise
micturition problems, symptoms in the area of thegastrointestinal tract, chemotherapy side effects, pro-
blems with defecation, stoma-related problems, male
and female sexual problems, and one single item on
weight loss. Completed questionnaires were scored
according to the instructions from the EORTC group.
Items are scored on a four-point scale from 1(”not at all)
to 4 (“very much”). Raw scores are aggregated and con-
verted to a linear scale ranging from 0 to 100, with
higher scores representing a higher level of functioning
or a higher level of symptoms [8]. Of the 38 items, 19
are applicable for all patients. The remaining 19 items
are applicable to sub-groups of patients: males, females,
patients who are sexually active, and patients with or
without stoma. All questions refer to the previous week,
with exception of sexual issues which have a 4-week
time frame [1].
Statistical analysis
Means and medians were both calculated for a more
comprehensive description of the data than when only
one of these summary statistics is used [9]. Missing
answers were dealt with according to the Scoring Man-
ual: if at least half of the items in the scale had been
completed, it was assumed that the missing item(s)
would have had values equal to the average of the items
present [8]. Ceiling and floor effect was explored
through proportion of respondents with maximum and
minimum scores, respectively.
Reliability
Internal consistency was evaluated by Cronbach’s alpha
coefficient. A coefficient value of at least 0.7 were con-
sidered acceptable [10].
Known-groups comparison
Methods of known-groups comparison were used to as-
sess the ability of the questionnaire to discriminate be-
tween subgroups of patients with different demographic
and clinical status. Comparison between subgroups was
only made where differences were expected [11]. Sub-
group comparisons included age (>64 years or ≤ 64
years), gender, type of cancer (colon or rectal cancer),
type of surgery (open or laparoscopic), presence of
stoma (with or without stoma), The American Society of
Anaesthesiologists (ASA) score was assigned by the sur-
geon and performance status was evaluated by the pa-
tient before surgery. Performance status and ASA score
were dichotomised. Performance status was divided into
“excellent or good” versus “more or less, less good or
bad”. ASA scores were divided into normal healthy
patients (ASA score I) versus patients with mild to se-
vere systematic disease (ASA score II-III).
Clinical significance is an important issue in the inter-
pretation of differences in HRQoL. For EORTC QLQ-
Table 1 Clinical and sociodemographic characteristics of
the study sample
Characteristics n = 164 Number (%) CI 95%
Age (range 39–83)
- Mean 63.8 62.4-65.2
- Median 64.0
Gender
- Female 60 (36.6) 29.1-44.0%
- Male 104 (63.4) 56.0-70.9%
Civil status
- Married 110 (67.1)
- Single 28 (17.1)
- Widow (er) 26 (15.9)
Asa-score
- I 60 (36.6)
- II 90 (54.9)
- III 14 (8.5)
Physical performance
- Excellent or good 81 (49.4)
- More or less 39 (23.8)
- Less good or bad 19 (11.6)
- Missing 25 (15.2)
Cancer type
- Colon 97 (59.1) 51.2-66.7%
- Rectum 67 (40.9) 33.3-48.8%
Surgery
- Laparotomy 103 (62.8)
- Laparoscopic 61 (37.2)
Surgery modality
- AR 56 (34.2)
- APR 14 (8.5)
- Right or transverse colon resection 40 (24.4)
- Left colon or sigmoideum resection 49 (29.9)
- Other 5 (3.1)
Stoma (temporary and definitive)
- Yes 55 (33.5) 24.7-39.4%
- No 108 (65.9) 56.8–71.9%
- Missing 1 (0.6) 0,0 -3.4%
Complications
- Surgical 25 (15.2)
- Medical 9 (5.5)
T-stadium
- T1 6 (3.7)
- T2 19 (11.6)
- T3 115 (70.1)
- T4 23 (14.0)
- Missing 1 (0.6)
Table 1 Clinical and sociodemographic characteristics of
the study sample (Continued)
Lymph node metastasise
- 0 90 (54.9)
- ≥ 1 72 (43.9)
- Missing 2 (1.2)
Postoperative Chemotherapy 50 (30.5)
- Missing 14 (8.5)
Preoperative radiation therapy 12 (7.3)
- Missing 24 (14.6)
* AR: Anterior resection APR: Abdominoperineal extirpation (APR).
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reflects small differences and 9–19 points indicates
medium differences [13]. Such ranges have not been
determined for EORTC QLQ-CR38. Based on measure-
ments with a variety of instruments, Fayers suggested
that a change of 5–10 points as being perceptible by the
patient and deemed by the patients as significant [14].
Accordingly, differences ≥ 5 points were accepted as a
clinical significant difference between subgroups in this
study. Group differences were assessed using the Mann-
Witney U-tests.
Convergent and discriminant validity
Analysis of convergent and discriminant validity were
used to examine whether items fit with their proposed
scale. Item convergent validity was defined as an item-
scale correlation of 0.40 or greater (corrected for over-
lap). Item discriminant validity was defined as an item
having a higher correlation with its own scale (corrected
for overlap) than with another scales [10]. Spearman’s
Rho was used.Results
Patients
One hundred and sixty seven (87.9%) of the patients
included in COLOR II and COLOFOL answered the
EORTC QLQ -CR38 one month after the operation. All
questionnaires were filled out by the patient themselves.
Clinical and sociodemographic data were missing for
three patients. In all, data from 164 patients (86.3%)
were available for further analysis.
Clinical and sociodemographic data are shown in
Table 1. The median age was 64 years. Seventy-nine
(59.2%) had colon cancer and 67 (40.8%) had rectal can-
cer. Stoma was present in 7.3% patients treated for colon
and 68.7% patients treated for rectal cancer.
It was not possible to obtain data about whether
patients had started postoperative chemotherapy when
they answered the questionnaire.
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The distribution of the answers for each item and scale
are shown in Table 2 (first column). The majority of
missing data were from items concerning sexuality
issues, with 7.9% -11% of the answers to sexual function-
ing missing. The answers to the sexual enjoyment item
as well as the two items concerning male and female
sexual problems were conditional on having been sexu-
ally active (item 49). Surprisingly, only 39 (37.5%) men
answered the item concerning sexual enjoyment, while
82 (78.8%) men answered the questions concerning male
sexual problems. There was a much lower response rate
to the equivalent questions among women. Only 14
(23.3%) women answered the question about sexual en-
joyment, and of those, 11 (18.3%) answered the ques-
tions concerning female sexual problems. The questions
about female sexual problems could not be further ana-
lysed due to the high number of missing values.
Score distribution
Mean, median, floor and ceiling values of the function
and symptom scales are presented in Table 2. The symp-
tom scores were heavily skewed towards the lower end.
The maximum score (100) was observed for micturition
problems, male sexual problems, and weight loss, but
not for other symptom scales. Functional scores were
high for body image, while lower values were observed
in future perspective, sexual function, and sexual enjoy-
ment. A floor and/or ceiling effect was observed for all
subscales and single items.
Internal consistency
Cronbach’s alpha coefficient for each scale is shown in
Table 2. A value exceeding the 0.70 criterion was
achieved in the body image, sexual function, male sexual
problems, defecation problems, and stoma-related pro-
blems scales. The criterion was not met in scales regard-
ing micturition problems (0.65), symptoms of the
gastrointestinal tract (0.55), female sexual problems
(0.35), or chemotherapy side effects (0.37).
Convergent and discriminant validity
The results of the convergent and disciminant validity
analyses are provided in Table 3. The criterion of 0.40
for convergent validity was fulfilled for all items in three
scales: body image, sexual functioning, and male sexual
problems. In the remaining scales of micturition pro-
blems, symptoms of the gastrointestinal tract, defecation
problems, and stoma-related problems, some of the
items did not display satisfactory convergent validity.
None of the items in the chemotherapy side effects scale
met the 0.40 criterion. In terms of discriminant validity,
the “irritated skin” item in the stoma-related problemsscale had a very low correlation with its own scale but a
higher correlation with the body image scale.
Known-groups comparison
Thirteen (50.0%) out of 26 comparisons distinguished
between clinical and demographic variables subgroups
of patients, with differences of five points or more. Mean
scores of the sub-groups are shown in Table 4. For three
of the scales, namely body image, male sexual problems
and defecation problems, the majority of comparisons
distinguished between the defined subgroups as antici-
pated. However, unexpectedly, a higher degree of
defecation problems was found in patients aged ≤ 64
than in the older group. Anticipated differences in sexual
functioning were only found in three out of five sub-
group comparisons. A lower score was expected for
patients with a stoma and patient treated with open sur-
gery, but this was not found. The symptoms of the
gastrointestinal tract scale could only distinguish be-
tween subgroups in one of two comparisons. As
expected, patients treated with open surgery had a
higher score compared with patients treated with laparo-
scopic surgery. A lower score for patients with rectal
cancer was expected but not found. For micturition pro-
blems and future perspective scales, only one out of
three anticipated differences were found. Difference in
future perspective was only found amongst patients with
different physical performance levels, where patients
with better performance status also had better future
perspective. The micturition problem scale could only
distinguish between genders. Anticipated differences in
relation to weight loss were not found in any
comparisons.
Discussion
This study examines the psychometric properties of
EORTC QLQ-CR38 in a sample of 164 Danish patients
with colorectal cancer, who were assessed one month
after primary open or laparoscopic surgery. In this study
data were obtained from two clinical studies one month
after operation. The sample included patients with or
without stoma and patients treated with different types
of surgical procedures. The proportion of patients trea-
ted with laparoscopic surgery was high in this study
compared with any other validation study of EORTC
QLQ-CR38 [15-17]. A postoperative setting was chosen,
in order to examine the performance of the question-
naire in reflecting function and symptoms after surgical
treatment. Known-groups comparisons were conducted
based on carefully prespecified hypotheses.
The body image, sexual functioning, defecation pro-
blems and male sexual problems scales could discrimin-
ate between the majority of the defined subgroups.
These scales also had a high convergent validity except
Table 2 Distribution of scores and Cronbach alpha of EORTC QLQ - CR38 in colorectal cancer patients
Scale Item number n = 164 (%) Mean (SD) Median Floor % Ceiling % Range Cronbach alpha
Micturition problems 159 (97.0) 24.3 (19.7) 22.2 22.0 0.6 0-100 0.65
31) Frequency urination day * 158 (96.3) 32.9 (28.4) 33.3 34.8 1.9 0-100
32) Frequency urination day night * 158 (96.3) 30.2 (27.8) 33 36.1 3.8 0-100
33) Pain while urinating* 159 (97.0) 10.1 (20.1) 0 76.7 0.6 0-100
Symptoms gastro-intestinal tract 163 (99.4) 18.9 (15.1) 20 15.3 0 0-80 0.55
34) Bloated feeling in stomach * 161 (98.2) 22.4 (26.8) 0 50.3 3.7 0-100
35) Abdominal pain * 161 (98.2) 23.0 (24.5) 33.3 46.0 1.2 0-100
36) Pain in buttocks 162 (98.8) 9.1(22.3) 0 82.7 2.5 0-100
37) Bothered by gas 162 (98.8) 27.4 (27.5) 33.3 42.0 2.5 0-100
38) Belching 163 (99.4) 12.9 (22.6 0 71.2 1.2 0-100
39) Weight loss 162 (98.8) 27.8 (31) 33.3 44.4 8.0 0-100
Chemotherapy side effects 163 (99.4) 15.8 (16.0) 11.1 33.7 0 0-83.3 0.37
40) Dry mouth* 162 (98.8) 23.7 (28.0) 33.3 64.4 5.0 0-100
41) Thin or lifeless hair 159 (97.0) 5.7 (15.1) 0 85.5 0.6 0-100
42) Trouble with taste 163 (99.4) 17.4 (27.6) 0 64.4 5.0 0-100
Body image * 163 (99.4) 80.4 (22.1) 88.9 1.2 36.8 0-100 0.78
43) Feeling less attractive * 163 (99.4) 80.2 (25.8) 100 2.5 55.8 0-100
44) Feeling less feminine/masculine * 162 (98.8) 84.4 (26.3) 100 3.7 67.9 0-100
45) Dissatisfied with body* 163 (99.4) 76.5 (27.7) 66.6 4.2 49.1 0-100
46) Future perspective * 163 (98.8) 57.5 (27.0) 66.7 6.7 16.0 0-100
Sexual function 151 (92.1) 20.1 (23.6) 16.7 46.4 0.7 0-100 0.85
47) Interest in sex * 151 (92.1) 23.6 (27.4) 0 50.3 2.0 0-100
48) Sexual activity 146 (89.0) 16.9 (23.2) 0 60.3 0.7 0-100
49) Sexual enjoyment 53 (32.3) 54.1 (36.5) 33.3 17.0 30.2 0-100
Male sexual problems 82 (78.8) 40.2 (38.4) 33.3 29.3 19.5 0-100 0.80
50) Problems erection* 82 (78.8) 45.5 (41.1) 33.3 34.1 24.3 0-100
51) Problems ejaculation 79 (76.0) 34.2 (42.7) 0 54.4 25.3 0-100
Female sex problems 11 (18.3) 19.7 (23.4) 16.7 45.5 0 0-66.7 0.35
52) Dry vagina 11 (18.3) 72.7 (36.0) 100 54.5 9.1 0-100
53) Pain during intercourse 11 (18.3) 12.1 (22.5) 0 72.7 0 0-66.6
Defecation problems (no stoma) 104 (96.3) 15.9 (13.8) 14.3 12.5 0 0-57.1 0.72
55) Frequent bowel movement day * 104 (96.3) 37.2 (28.8) 33.3 25.0 6.7 0-100
56) Frequent bowel movement night* 104 (96.3) 17.9 (27.4) 0 63.5 3.9 0-100
57) Urge without stools 105 (97.2) 22.9 (27.1) 0 50.5 2.9 0-100
58) Unintentional release of stools 104 (97.2) 8.0 (17.1) 0 79.8 0 0-66.7
59) Blood with stools * 104 (96.3) 1.3 (6.44) 0 96.2 0 0-33
60) Difficulty in moving bowels 105 (97.3) 16.2 (23.6) 0 62.9 1.0 0-100
61) Painful bowel movement 105 (97.3) 8.6 (17.9) 0 79.1 0 0-66.7
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Table 2 Distribution of scores and Cronbach alpha of EORTC QLQ - CR38 in colorectal cancer patients (Continued)
Stoma-related problems 51 (92.7) 25.8 (20.8) 19.0 5.9 0 0-90.5 0.81
62) Afraid stoma noise 51 (92.7) 25.5 (32.4) 0 52.9 7.8 0-100
63) Afraid smell stools 51 (92.7) 27.5 (35.7) 0 54.9 11.8 0-100
64) Worry about leakage 51 (92.79 40.5 (33.5) 33.3 27.5 13.7 0-100
65) Caring for stoma* 50 (90.9) 16.7 (27.1) 0 66.0 3.9 0-100
66) Irritated skin 51 (92.7) 25.5 (27.1) 33.3 41.2 5.9 0-100
67) Embarrassment 51 (92.7) 19.6 (27.6) 0 58.8 3.9 0-100
68) Feeling less complete 52 (94.5) 26.3 (29.8) 33.3 46.2 5.8 0-100
(SD) Standard deviation.
* Indicates scales and items included in EORTC QLQ-CR29.
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similar to the original validation. In the original study,
convergent, and discriminant analysis confirmed the
structure of the functional scales, but did not strongly
support the structure of the symptoms scales [1]. With
regards to internal consistency, three of the symptoms
scales, namely micturition problems, symptoms of the
gastrointestinal tract, and chemotherapy side effects
had low Cronbach`s alpha coefficients (0.37-0.65), but
this is comparable to the original validation [1] and
some other subsequent studies [16,17]. In previous
studies, the psychometric problems shown in the symp-
toms scales have been attributed to the fact that symp-
toms and side-effects do not necessarily occur together,
which makes it difficult to cluster items in a meaningful
way [17], and thus raising doubt about the usefulness
of these scales.
A limitation of this study could be the homogeneity of
the population in relation to disease stage, disease sever-
ity and performance status. This may underlie a nar-
rower response range and lead to low data variability,
which could have compromised the known-group com-
parison results. It is well-known that the strength of cor-
relations, including Cronbach’s alpha, increases with
data variability. The low variability in this data set,
reflected in the skewness towards high functional scores
and low symptoms scores, may partially account for the
less than ideal validity results. A low correlation between
items and scales was particularly evident in some symp-
tom scales: symptoms of the gastrointestinal tract, the
pain while urinating item in the micturition problems
scale and all items concerning chemotherapy side effects.
The low correlation for chemotherapy side effects was
probably attributable to the low proportion of patients
undergoing chemotherapy.
The weight loss item could not distinguish between
any of the subgroups. A floor effect was observed for
this item, indicating low variability. This could be due to
the time reference in the item. The patient is asked to
answer the question in relation to the past week,
whereas weight loss may have occurred prior to that.This item also demonstrated a low validity in another
validation study and has been eliminated from the
updated version [16].
It was not possible to carry out known-groups com-
parison for stoma related problems. The stoma related
problems scale is only applicable to patients with stoma,
and the number of such patients was too small for fur-
ther division into subgroups.
The amount of missing data associated with the sexual
problems and enjoyment scales rendered known-groups
comparison analysis impossible. These questions are
conditional on the patient being sexually active. The ori-
ginal EORTC QLQ-CR38 validation study also found a
high rate of missing values in these questions, where
both male (3%) and female (12%) found them too intru-
sive and chose not to answer [1]. Since there is no spe-
cific question asking whether the patient is sexually
active, reasons for non-response could not be differen-
tiated (sexually inactive versus unwillingness to answer).
In addition, at just one month after surgery, the propor-
tion of sexually active patients may have been lower than
usual. Reluctance of women to respond to questions
about their sex life has been well described, which may
partially account for the especially high missing values
seen in the female sexual problems scale [15,16,18,19].
The capability of the Danish version of EORTC QLQ-
CR38 to capture changes over time was not examined in
this study, but responsiveness is an important feature of
a questionnaire. Responsiveness has been examined in
some of the studies validating EORTC QLQ-CR38
[1,15]. The body image, defecation problems, micturition
problems, and symptoms of the gastrointestinal tract
scales have been reported responsive to treatment-
induced change over time. Lack of responsiveness has
been reported for the chemotherapy side-effects scale
[1,15,20]. One study found the EORTC QLQ-C30 to be
more responsive in patients receiving chemotherapy
than the EORTC QLQ-CR38 [20]. In addition to the val-
idation studies, some studies have used EORTC QLQ-
CR38 for prospective follow-up. The same scales as in
the validation studies as well as the scales addressing
Table 3 Item convergent and discriminat validity EORTC QLQ-CR38 (Spearman’s RHO)
Scales Items MI GI CT BI SXS MSX FSX DF STO
Micturition problems (MI)
31) Frequency of urination day 0.56 0.15 0.07 0.15 0.08 0.31 0.34 0.03
32) Frequency of urination night 0.56 0.22 0.16 0.11 0.01 0.16 0.31 0.17
33) Pain while urinating 0.27 0.10 0.04 0.04 0.06 0.22 0.18 0.08
Symptoms gastro-intestinal tract (GI)
34) Bloated feeling in stomach 0.05 0.42 0.18 0.19 0.07 0.07 0.18 0.16
35) Abdominal pain 0.13 0.38 0.24 0.30 0.01 0.01 0.07 0.24
36) Pain in buttocks 0.05 0.06 0.04 0.16 0.04 0.27 0.16 0.20
37) Bothered by gas 0.18 0.31 0.03 0.12 0.10 0.12 0.25 0.27
38) Belching 0.07 0.20 0.22 0.17 0.15 0.32 0.09 0.19
Chemotherapy side effects (CT)
40) Dry mouth 0.17 0.18 0.29 0.18 0.20 0.25 0.32 0.06
41) Thin or lifeless hair 0.07 0.18 0.14 0.06 0.12 0.08 0.06 0.08
42) Trouble with taste 0.03 0.16 0.29 0.27 0.18 0.14 0.24 0.02
Body image (BI)
43) Feeling less attractive 0.14 0.28 0.25 0.59 0.12 0.32 0.21 0.43
44) Feeling less feminine/masculine 0.16 0.21 0.12 0.66 0.07 0.38 0.19 0.37
45) Dissatisfied with body 0.14 0.30 0.21 0.49 0.03 0.33 0.22 0.29
Sexual function (SXS)
47) Interest in sex 0.09 0.05 0.26 0.06 0.71 0.37 0.09 0.07
48) Sexual activity 0.02 0.05 0.24 0.07 0.71 0.41 0.00 0.16
Male sexual problems (MSX)
50) Problems erection 0.23 0.14 0.30 0.39 0.40 0.66
51) Problems ejaculation 0.25 0.10 0.13 0.40 0.34 0.66
Female sexual problems (FSX)
52) Dry vagina
53) Pain during intercourse
Defalcation problems (DF)
55) Frequent bowel movement day 0.43 0.27 0.11 0.12 0.04 0.26 0.44
56) Frequent bowel movement night 0.36 0.18 0.10 0.20 0.02 0.35 0.45
57) Urge without stools 0.21 0.21 0.26 0.26 0.12 0.38 0.56
58) Unintentional release of stools 0.21 0.22 0.20 0.14 0.14 0.34 0.36
59) Blood with stools 0.23 0.17 0.10 0.08 0.02 0.02 0.22
60) Difficulty in moving bowels 0.02 0.10 0.25 0.15 0.01 0.24 0.27
61) Painful bowel movement 0.21 0.14 0.26 0.11 0.04 0.13 0.30
Stoma-related problems (STO)
62) Afraid stoma noise 0.28 0.44 0.16 0.43 0.20 0.56
63) Afraid smell stools 0.35 0.36 0.06 0.48 0.04 0.60
64) Worry about leakage 0.18 0.18 0.20 0.33 0.11 0.59
65) Caring for stoma 0.12 0.03 0.18 0.08 0.09 0.35
66) Irritated skin 0.07 0.08 0.12 0.41 0.26 0.06
67) Embarrassment 0.09 0.29 0.13 0.48 0.12 0.57
68) Feeling less complete 0.13 0.28 0.10 0.43 0.02 0.60
Bolding indicate correlation coefficient > 0.40.
Thickly outlined boxes indicate correlation with own scale corrected for over-lap.
Analysis were not possible for the scales female sexual (FSX) problems n < 11 and male sexual problems (MSX) correlated with stoma-related problems (STO)
n ≤ 28.
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Table 4 Known-groups comparison for the relevant scales
Scales
(Item number)
Age Gender Physical performance Type cancer Stoma Type surgery Physical status
<64 years vs.
>64 years
P- value Male vs.
female
P-value Excellent or good vs.
less good or bad
P-value Colon vs.
rectum




P-value ASA 1 vs.
ASA 2-3
P-value
n = 77/87 n = 104/60 n = 81/57 n = 87/21 n = 110/53 n = 101/61 n = 55/99
Micturition problems
(31–33)




20 vs. 18 0.14 22 vs. 14 0.007
Weight loss (39) 13 vs. 21 0.07 26 vs. 19 0.46 29 vs. 26 0.9
Chemotherapy side
effects (40–42)
Body image (43–45) 84 vs. 75 0.02 84 vs. 73 0.001 78 vs. 83 0.07
Future Perspective
(46)
55 vs. 60 0.45 65 vs. 50 0.001 57 vs. 58 0.88
Sexual functioning
(47–48)









20 vs. 12 0.009 18 vs. 13 0.2 14 vs. 24 0.004
Stoma-related
problems (62–68)
Mean score and P-value for between-groups differences.
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and chemotherapy side-effects were found to be able to
detect relevant differences over time in different treat-
ment groups of patients with colorectal cancer [21-29].
Thus, considerable evidence for the responsiveness to
change has been found.
There were several reasons for the revision of EORTC
QLQ-CR38 into the shorter version EORTC QLQ-CR29.
These included changes in the treatment of colorectal
cancer, problems with missing data, and that the EORTC
QLQ-CR38 contains scales that are unique to sub-
groups of patients [3,4]. The items and scales from
EORTC QLQ-CR38 which remained unchanged in
the EORTC QLQ-CR29 are highlighted in Table 2. The
EORTC QLQ-CR29 contains 17 unchanged items from
EORTC QLQ-CR38, five reworded items, and seven new
items [3,4]. The EORTC QLQ-CR29 can be summarized
into four scales: body image, urinary frequency, blood or
mucus and stool frequency. The body image scale was
the only scale that remained unchanged from the
EORTC QLQ-CR38, a decision that is supported by its
satisfactory psychometric performance found in this
study. The micturition problems scale was changed to
urinary frequency, and the pain with urination item was
removed from the scale due to poor convergent validity,
a finding which was replicated in this study. The symp-
toms in gastro-intestinal tract scale was split into single
items (some items were removed and some were
reworded). The results of this study support the alter-
ation of both micturition problems scale and the gastro-
intestinal tract scale, due to their low convergent validity
and known-group validity. The scales concerning stoma
and defecation problems were split into single items and
were standardised, so that patient response could be
compared where possible. The question concerning
weight loss has been re-worded from:” Have you lost
weight?” to “Have you worried about your weight?”
Again, this is supported by this study, as the change may
make it easier for the patient to answer. The psychomet-
ric properties of the scales concerning sexual functioning
and male sexual problems were good, but the amounts
of missing values were high. In the EORTC QLQ-CR29,
several changes have been made with the aim of redu-
cing missing data in the sexual domain. First, items in
this domain have been cut down to two items for men
and two items for women: one of which addresses
interest in sex and the other addresses sexual problems.
Second, the answers are not conditional on being sexu-
ally active. Third, these items are moved to the end of
questionnaire. These changes may reduce missing
values, but at the same time would also decrease the
information related to sexual functioning after treat-
ment for colorectal cancer, which is an important as-
pect of outcome.Conclusions
In conclusion, the Danish version of EORTC QLQ-CR38
showed satisfactory psychometric properties for the
scales concerning body image, sexual functioning, male
sexual problems and defecations problems. Reduced psy-
chometric properties were found especially for the fol-
lowing symptom scales: micturition problems, symptoms
of the gastrointestinal tract, and weight loss, which could
partially be explained by the homogeneity of the study
population. Although the stoma related problems
scale showed good internal consistency and convergent
validity, no clear conclusion could be drawn regarding
its psychometric performance, as known-groups
comparison could not be conducted. Evaluation of the
psychometric properties of the scale chemotherapy side
effects was limited by the low number for patients re-
ceiving chemotherapy. It was not possible to assess the
psychometric properties of the female sex problems and
sexual enjoyment scales due to a high number of missing
values.
According to the results of this study, the update of
EORTC QLQ-CR38 to the EORTC QLQ-CR29 seems
appropriate [3,4]. The results also suggest that EORTC
QLQ-CR29 is likely to be a more valid instrument.
Nevertheless, a proper validation of this questionnaire in
a Danish setting is required.
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